Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Nasha Zhang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

N. Zhang1, M. Yang2, H. Xing2, J. Liu2

Author affiliations

  • 1 Department Of Radiation oncology, Shandong Cancer Hospital, 250117 - Ji'nan/CN
  • 2 Shandong Provincial Key Laboratory Of Radiation oncology, Cancer Research Center, Shandong Cancer Hospital, 250117 - Jinan/CN
More

Resources

Abstract 1168

Background

As a mostly used epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), gefitinib significantly prolongs survival of lung adenocarcinoma patients with EGFR mutations. However, more than 10% of EGFR mutation-positive patients do not respond and a substantial fraction of responded patients progress after 8-12 months’ treatment. Identification of new biomarkers for EGFR-TKIs prognosis is vital. The objective of this study is to explore associations between MDM4 genetic variant and survival of lung adenocarcinoma patients treated with gefitinib.

Methods

384 patients with stage IIIB or IV lung adenocarcinoma were recruited between January 2009 and June 2013. Patients were treated with gefitinib orally at a daily dose of 250 mg as 1st-line monotherapy. MDM4 rs4245739 A>C genotypes were determined using MassArray system. Dual luciferase reporter gene assays evaluated the function of MDM4 rs4245739 genetic variant in lung adenocarcinoma cell lines A549 and H1299. The differences of patient clinical characteristics were calculated by student's t test or χ2 test. Survival differences were examined by log-rank test. Multivariate Cox regression analysis assessed prognostic factors for PFS or OS. Two-sided P < 0.05 indicated a significant difference.

Results

Among 384 patients, EGFR mutations were positive in 181 patients (47.1%). Median progression-free survival (PFS) and overall survival (OS) for all patients with the rs4245739AC genotype were significantly longer than that of the AA carriers (PFS: 22.9vs.10.9 months, P < 0.001; OS: 27.3vs.16.5 months, P = 0.003). Notably, in the EGFR mutation-positive subgroup, individuals with MDM4 rs4245739AC genotype showed 14.1 months prolonged PFS (28.8 months vs. 14.7 months; P = 0.022) and 12.2 months prolonged OS (31.4 months vs. 19.2 months; P = 0.047) compared to the AA group. Reporter gene assays showed that the rs4245739A allele leads to significantly increased MDM4 expression in lung adenocarcinoma cells compared to the C allele (P < 0.05).

Conclusions

MDM4 rs4245739 genotypes may act as prognostic biomarker for patients’ survival to gefitinib therapy and offer help to individualized treatment in lung adenocarcinoma patients with EGFR mutations.

Clinical trial identification

Legal entity responsible for the study

Nasha Zhang.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings